The British Medical Journal has featured an “Analysis” article that discusses the off-label use of recombinant factor VIIa (rFVIIa) for major haemorrhage, to provide insights into the forces driving off-label prescribing and to illustrate some of the limits to evidence based medicine.

Please see link below for details.